subLetter Ausgabe 05/2021 (September 2021)
Inhalt:
Therapie: Orales slow-release Morphin: Erste Langzeitdaten unter Alltagsbedingungen fallen positiv aus
Kassenabrechnung: Die Vorschläge der DGS zur Überarbeitung des EBM
Befragung: Opioidsubstitution und SARS-CoV-2-Arzneimittel-Versorgungsverordnung
KVQS: Covid-19 und Substitution: „Notlösungen“ – oder Optionen für die Zukunft?
Interview: „COA.KOM soll das Versorgungsnetz für Kinder aus Suchtfamilien verbessern!“
Arzneimittel-Abrechnung: Hash-Codes bei der Rezeptabrechnung in Apotheken – die Folgen für Ärzte bei der Rezeptausstellung
Zugang für Fachkreise, Anmeldung erforderlich
Ärztliche Tabakentwöhnung: Wirksamkeit und Potenziale
Dtsch Arztebl 2021; 118(37): A-1635 / B-1356
Batra, Anil; Kunstmann, Wilfried
https://www.aerzteblatt.de/archiv/221166
Irland. Substance Use Strategy 2021-31: Preventing Harm - Empowering Recovery -- A - Strategic Framework to Tackle the Harm from Substance Use (2021-31) (Department of Health, 2021)
https://www.drugsandalcohol.ie/34827/1/doh-substanceuse-strategy-2021-31.pdf
Nitrous oxide: How to take laughing gas as safely as possible
(…) Metro.co.uk spoke to Guy Jones, senior scientist at The Loop, which works to reduce the harm caused by drugs.
He gave us top tips on how to take laughing gas in the safest way possible. (Metro, UK, 10.09.2021)
https://metro.co.uk/2021/09/10/nitrous-oxide-how-to-take-nitrous-oxide-as-safely-as-possible-15207122
Estland. Key Lessons from Estonia. SO-PREP, 2021.
Oja,M.; Kurbatova, A.; Abel-Ollo, K.
The National Institute for Health Development, Estonia, ISBN: 978-952-343-019-8
https://so-prep-project.eu/wp-content/uploads/2021/08/D2.3-Key-lessons-from-Estonia-final_label.pdf
‘Treatment in Liberty’ - Human Rights and Compulsory Detention for Drug Use
Rick Lines, Julie Hannah, Giada Girelli,
Human Rights Law Review, 2021;, ngab022, doi.org/10.1093/hrlr/ngab022
https://www.ohchr.org/Documents/Issues/Detention/Call/Others/treatment-in-liberty-lines-hannah-girelli.pdf
Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database.
Saloner B, Whitley P, LaRue L, Dawson E, Huskey A.
JAMA Netw Open. 2021;4(9):e2123019. doi:10.1001/jamanetworkopen.2021.23019
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784053
Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence.
Lintzeris N, Dunlop A, Masters D (2019)
NSW Ministry of Health, Sydney Australia
https://www.health.nsw.gov.au/aod/Publications/full-depot-bupe-interim-gl.pdf
A Vaccine to Treat Opioid Disorders: First Participant Enrolled in Trial
A vaccine that prevents oxycodone from entering the brain? This might be the safe, long-lasting, cost-effective solution for opioid use disorders. (Psychiatric Times, USA, 15.09.2021)
https://www.psychiatrictimes.com/view/vaccine-to-treat-opioid-disorders-first-participant-enrolled-in-trial
Wo die Spiritualität im Gehirn verortet ist
Boston – Wissenschaftler des Brigham and Women’s Hospital in Boston meinen, Spiritualität und Religiosität in einem bestimmten Gehirnschaltkreis lokalisieren zu können. Sie berichten darüber im Fachmagazin Biological Psychiatry (2021; DOI: 10.1016/j.biopsych.2021.06.016) (aerzteblatt.de, 11.08.2021)
https://www.aerzteblatt.de/nachrichten/125556/Wo-die-Spiritualitaet-im-Gehirn-verortet-ist
Das „Psycho“ im biopsychosozialen Modell der Sucht – die psychologischen Zugänge zur Entstehung und Behandlung
Michael Klein, addiction.de, 12.09.2021
https://www.addiction.de/modell-der-sucht/
Irland. Experts want pilot project to test drugs at music festivals
(…) The report of the HSE-led working group recommends a limited pilot project at festivals – described as ‘back of house’ drug checking – whereby tests are conducted on substances dropped into amnesty bins or following seizures by gardaí or security with no direct interaction with drug users.
These are different from more extensive ‘front of house’ drug checking systems – common at festivals and nightclubs abroad – where people directly hand over substances for analysis and receive results and allow for face-to-face health advice. (Irish Examiner, Irland, 17.09.2021)
https://www.irishexaminer.com/news/arid-40700003.html
Investigation on heroin and cocaine quality in Luxembourg.
Bourmaud, A., Dahm, G., Meys, F. et al.
Harm Reduct J 18, 97 (2021). doi.org/10.1186/s12954-021-00544-x
https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-021-00544-x
Third party drug checking: accessing harm reduction services on the behalf of others.
Larnder, A., Burek, P., Wallace, B. et al.
Harm Reduct J 18, 99 (2021). doi.org/10.1186/s12954-021-00545-w
https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-021-00545-w
Strategies to maximise study retention and limit attrition bias in a prospective cohort study of men reporting a history of injecting drug use released from prison: the prison and transition health study.
Stewart, A.C., Cossar, R., Walker, S. et al.
BMC Med Res Methodol 21, 185 (2021). doi.org/10.1186/s12874-021-01380-0
https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-021-01380-0
Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail.
Lee JD, Malone M, McDonald R, et al.
JAMA Netw Open. 2021;4(9):e2123032. doi:10.1001/jamanetworkopen.2021.23032
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784022
US national randomized study to guide how best to reduce stigma when describing drug-related impairment in practice and policy.
Kelly, J. F., Greene, M. C., and Abry, A. (2021) A
Addiction, 116: 1757– 1767. doi.org/10.1111/add.15333
https://onlinelibrary.wiley.com/doi/full/10.1111/add.15333
Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.
Johnson K, Hills H, Ma J, Brown CH, McGovern M.
Am J Drug Alcohol Abuse. 2021 Mar 4;47(2):220-228. doi: 10.1080/00952990.2020.1824236. Epub 2020 Oct 15. PMID: 33054435; PMCID: PMC8046836.
https://www.tandfonline.com/doi/full/10.1080/00952990.2020.1824236
LSD degrades hippocampal spatial representations and suppresses hippocampal-visual cortical interactions
Domenico, Carli et al.
Cell Reports, Volume 36, Issue 11, 109714
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01163-3
"Areca Nut Chewing: Initiation, Addiction, and Harmful Effects Emphasizing the Barriers and Importance of Cessation",
I.A. Athukorala, W. M. Tilakaratne, R. D. Jayasinghe,
Journal of Addiction, vol. 2021, Article ID 9967097, 9 pages, 2021., doi.org/10.1155/2021/9967097
https://www.hindawi.com/journals/jad/2021/9967097/
More Women Using Cannabis for Menopause Symptoms
New study documents high percentage of women have tried cannabis to help manage their menopause symptoms.
NAMS - The North American Menopause Society, 22.09.2021
http://www.menopause.org/docs/default-source/press-release/cannabis-use-for-menopause-symptoms.pdf
Notes from the Field: Xylazine Detection and Involvement in Drug Overdose Deaths — United States, 2019.
Kariisa M, Patel P, Smith H, Bitting J.
MMWR Morb Mortal Wkly Rep 2021;70:1300–1302. DOI: doi.org/10.15585/mmwr.mm7037a4
https://www.cdc.gov/mmwr/volumes/70/wr/mm7037a4.htm
Neurocognitive impairments and brain abnormalities resulting from opioid-related overdoses: A systematic review.
Winstanley EL, Mahoney JJ 3rd, Castillo F, Comer SD.
Drug Alcohol Depend. 2021 Sep 1;226:108838. doi: 10.1016/j.drugalcdep.2021.108838. Epub 2021 Jun 24. PMID: 34271512.
Abstract
https://pubmed.ncbi.nlm.nih.gov/34271512/
Anti-Fentanyl Vaccines as Medical Solutions to Overdose Deaths
Thomas R. Kosten, MD
Manufactured fentanyl is a major cause of overdoses for opioids and nonopiods. Can a vaccine immunize against overdose? (Psychiatric Times, USA, 10.08.2021)
https://www.psychiatrictimes.com/view/anti-fentanyl-vaccines-as-medical-solutions-to-overdose-deaths
“Disparities in Opioid Overdose Death Trends by Race/Ethnicity, 2018–2019, From the HEALing Communities Study”,
Marc R. Larochelle, et al.
American Journal of Public Health , no. (): pp. e1-e4., doi.org/10.2105/AJPH.2021.306431
https://ajph.aphapublications.org/doi/pdf/10.2105/AJPH.2021.306431
Rizmoic® - Wirkstoff Naldemedin (PAMORA - peripher wirkende μ-Opioidrezeptor-Antagonisten)
Schmerz.de -> Nebenwirkungen
https://www.schmerz.de/startseite
Naldemedin|Rizmoic®|60|2020
Pharmazeutische Zeitung, 29.05.2020
https://www.pharmazeutische-zeitung.de/arzneistoffe/daten/2020/naldemedinrizmoicr602020/
Neue Arzneimittel: Naldemedin (Rizmoic®)
Zugelassene Indikation und Wirkmechanismus
Rizmoic® (Naldemedin) ist zur Behandlung von opioidinduzierter Obstipation (OIC, opioid-induced constipation) bei Erwachsenen zugelassen, die früher bereits mit einem Abführmittel behandelt wurden. Naldemedin ist ein Naltrexon-Derivat, das chemisch so verändert wurde, dass es die Blut-Hirn-Schranke nicht überqueren kann. Zudem ist Naldemedin ein Substrat des P-Glykoprotein (P-gp)-Effluxtransporters, der möglicherweise ebenfalls dazu beiträgt, dass Naldemedin nicht in das ZNS eindringt. Naldemedin antagonisiert die Opioid-Bindung an den µ-, δ- und κ-Opioidrezeptoren im Gastrointestinaltrakt und vermindert dadurch die obstipierenden Wirkungen von Opioiden ohne die ZNS-vermittelten Opioideffekte aufzuheben. Der pharmazeutische Unternehmer gab bei der Zulassung an, dass Naldemedin aufgrund seiner langsamen Assoziations- und Dissoziationskinetik am μ-Opioidrezeptor vermutlich als nicht kompetitiver Antagonist wirkt, sodass die antagonistische Wirkung auch bei höheren Opioidkonzentrationen aufrechterhalten bleibt. Diese Annahme basierte auf Ergebnissen präklinischer Studien. Der Ausschuss für Humanarzneimittel der EMA beschrieb im European Public Assessment Report Naldemedin aber eher als kompetitiver Antagonist, sodass ein sogenannter Ceiling-Effekt nicht ausgeschlossen werden kann.
Arzneimittelkommission der deutschen Ärzteschaft, 22.06.2020
https://www.akdae.de/Arzneimitteltherapie/AVP/Artikel/2020-3-4/129h/index.php
Contingency Management Programme Team. Using a pragmatically adapted, low-cost contingency management intervention to promote heroin abstinence in individuals undergoing treatment for heroin use disorder in UK drug services (PRAISE): a cluster randomised trial.
Metrebian N, Weaver T, Goldsmith K, Pilling S, Hellier J, Pickles A, Shearer J, Byford S, Mitcheson L, Bijral P, Bogdan N, Bowden-Jones O, Day E, Dunn J, Glasper A, Finch E, Forshall S, Akhtar S, Bajaria J, Bennett C, Bishop E, Charles V, Davey C, Desai R, Goodfellow C, Haque F, Little N, McKechnie H, Mosler F, Morris J, Mutz J, Pauli R, Poovendran D, Phillips E, Strang J;
BMJ Open. 2021 Jul 1;11(7):e046371. doi: 10.1136/bmjopen-2020-046371. PMID: 34210725; PMCID: PMC8252884.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252884/
Seite 1 von 8